Pharma Marketing Network

I did not attend the ePharma Summit today -- I just had too much work to do here in the office taking care of...

After 4 days of R&R down in Miami, FL, I am back tending to my flock (of social networks, blogs, clients, subscribers) and trying...

Another Friday and another installment of the "Bob & John" show; ie, Bob Ehrlich (DTC Perspectives) and me, John Mack (Pharma Marketing News) debate...

Creating the Right Physician Experiences To Drive Business. The Vast Majority of Pharmaceutical Companies across the US and Europe Say They Are Moving from Traditional Sales Models to New Service Models. But Are Doctors Experiencing Any Real Change?

Yesterday, I posted comments made by Pfizer's global PR chief, Ray Kerins, who asked "How in the hell do we have such a...

Over the past 20 months, Pfizer's global PR chief, Ray Kerins re-organized the company's press relations office to "manage" journalists, according to this 3-minute...

This article summarizes a recent discussion between eyeforpharma's Editor Lisa Roner and Hans Nagl, Promotion Response Modelling Manager, Shire, about how the current economy and changing pharma landscape is impacting program effectiveness measures.

The pharmaceutical industry must find ways to utilize the new media tools that other industries use while ensuring compliance with FDA regulations. The good news is we can! The author summaries the content of the book and offers practical guidelines for the pharma marketers.

This article presents a summary of a recent TNS Healthcare webinar and personal conversations with presenters conducted beforehand. Included are NEW research results about how US and European physicians rate pharmaceutical companies against a number of customer value points that are important in achieving success with the new sales model.

This article presents a summary of a recent TNS Healthcare webinar and personal conversations with presenters conducted beforehand. Included are NEW research results about how US and European physicians rate pharmaceutical companies against a number of customer value points that are important in achieving success with the new sales model.